PapersFlow Research Brief
Cancer Immunotherapy and Biomarkers
Research Guide
What is Cancer Immunotherapy and Biomarkers?
Cancer immunotherapy and biomarkers refers to treatments that harness the immune system against tumors, primarily through immune checkpoint blockade targeting PD-1 and PD-L1, alongside biomarkers such as tumor mutational burden, PD-L1 expression, and mismatch-repair status that predict response to these therapies.
Research encompasses 134,991 works on immune checkpoint blockade, tumor microenvironment influences, T-cell exhaustion, neoantigens, and combination therapies. Key studies demonstrate anti-PD-1 antibodies yield objective responses in 20-25% of patients with non-small-cell lung cancer, melanoma, or renal-cell cancer, with PD-L1 expression on tumors linked to better outcomes. Clinical trials like KEYNOTE-024 show pembrolizumab extends progression-free and overall survival in PD-L1-positive non-small-cell lung cancer compared to chemotherapy.
Topic Hierarchy
Research Sub-Topics
PD-1/PD-L1 Checkpoint Inhibitors
Researchers develop monoclonal antibodies like pembrolizumab and nivolumab, studying binding kinetics, epitope specificity, and resistance mutations. Clinical trials evaluate efficacy across solid tumors with varying PD-L1 expression.
Tumor Mutational Burden as Biomarker
This sub-topic validates TMB measured by whole exome sequencing as predictor of immunotherapy response independent of PD-L1. Studies standardize thresholds and explore MSI-high subsets with extreme TMB.
T Cell Exhaustion in Cancer
Investigators characterize progressive epigenetic dysfunction in tumor-infiltrating lymphocytes marked by PD-1, TIM-3, LAG-3. Research develops exhaustion reversal strategies combining checkpoint blockade with metabolic modulation.
Neoantigen Identification and Vaccines
Researchers integrate tumor sequencing with HLA binding prediction to design personalized neoantigen vaccines and TCR therapies. Clinical studies combine neoantigen targeting with checkpoint blockade for synergy.
Immune-Related Adverse Events Management
This area studies incidence, pathophysiology, and corticosteroid-refractory toxicities affecting endocrine, dermatologic, and gastrointestinal systems. Guidelines evolve for balancing ICI continuation with organ-specific immunosuppression.
Why It Matters
Cancer immunotherapy via PD-1/PD-L1 blockade improves survival in specific cancers; for example, in KEYNOTE-024, pembrolizumab doubled progression-free survival to 10.3 months versus 6.0 months with chemotherapy in PD-L1-positive non-small-cell lung cancer patients. Nivolumab outperformed docetaxel in advanced nonsquamous non-small-cell lung cancer (CheckMate 057), extending median overall survival to 12.2 months from 9.4 months. Mismatch-repair deficiency predicts benefit from PD-1 blockade, as shown in a 2015 trial where pembrolizumab induced responses in colorectal and other tumors. These advances apply to breast cancer, with Hartkopf et al. (2016) highlighting PD-1/PD-L1 inhibition's antitumor activity. Biomarkers like PD-L1 expression guide patient selection across melanoma, lung, and renal cancers, reducing ineffective treatments and adverse events.
Reading Guide
Where to Start
"PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer" by Hartkopf et al. (2016), as it provides a focused introduction to checkpoint inhibition's antitumor activity and potential for durable control in a common cancer, with 30,893 citations.
Key Papers Explained
Pardoll (2012) in "The blockade of immune checkpoints in cancer immunotherapy" outlines foundational mechanisms of PD-1/PD-L1 blockade. Topalian et al. (2012) in "Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer" builds on this with clinical data showing 20-25% response rates linked to PD-L1 expression. Reck et al. (2016) in "Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer" extends to head-to-head trials, proving superior survival; Borghaei et al. (2015) in "Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-Cell Lung Cancer" and Brahmer et al. (2015) in "Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer" confirm nivolumab's benefits across NSCLC subtypes regardless of PD-L1 levels.
Paper Timeline
Most-cited paper highlighted in red. Papers ordered chronologically.
Advanced Directions
Recent preprints emphasize multi-omics for breast cancer biomarkers and longitudinal liquid biopsies like ctDNA for head and neck cancers. Mount Sinai findings show PD-1 therapy coordinates antibodies and T cells. Grants to City of Hope ($23.7M) and University of Houston ($3M) fund biomarker mapping and immunotherapy cores.
Papers at a Glance
| # | Paper | Year | Venue | Citations | Open Access |
|---|---|---|---|---|---|
| 1 | PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer | 2016 | Breast Care | 30.9K | ✓ |
| 2 | AJCC Cancer Staging Manual | 2016 | — | 17.4K | ✕ |
| 3 | Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narra... | 2017 | American Journal of Ne... | 15.3K | ✓ |
| 4 | The blockade of immune checkpoints in cancer immunotherapy | 2012 | Nature reviews. Cancer | 13.4K | ✓ |
| 5 | Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody ... | 2012 | New England Journal of... | 12.4K | ✓ |
| 6 | Immunity, Inflammation, and Cancer | 2010 | Cell | 10.4K | ✓ |
| 7 | Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small... | 2016 | New England Journal of... | 9.7K | ✓ |
| 8 | Nivolumab versus Docetaxel in Advanced Nonsquamous Non–Small-C... | 2015 | New England Journal of... | 9.3K | ✓ |
| 9 | PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | 2015 | New England Journal of... | 9.2K | ✓ |
| 10 | Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small... | 2015 | New England Journal of... | 8.4K | ✓ |
In the News
FDA Oncology Update January 2026: New Horizons in ...
* Sevabertinib and zoldonrasib received breakthrough therapy designations for specific NSCLC mutations, highlighting advancements in targeted lung cancer treatments.
City of Hope Awarded $23.7 Million to Map Biomarkers
News & World Report, has been awarded an up to $23.7 million contract from the Advanced Research Projects Agency for Health (ARPA-H) within the U.S. Department of Health and Human Services. The gra...
University of Houston Awarded $3M to Launch Cancer ...
As part of a $93 million grant package, the Cancer Prevention and Research Institute of Texas, known for funding groundbreaking projects, has awarded the University of Houston $3 million to set up ...
Clinical Trial Updates: New Frontiers in Cancer ...
Innovations in clinical trials now emphasize responsive biomarkers like circulating tumor DNA (ctDNA) and tumor mutation burden to tailor immunotherapy. Trials using ctDNA testing have enabled real...
OncoHost wins €2.5m grant to advance precision oncology
OncoHost has secured a €2.5m ($2.8m) grant from the EIC Transition Programme, an initiative under the EU’s broader Horizon Europe funding programme, to develop a novel biomarker capable of predicti...
Code & Tools
This work was mainly performed using python 3.9.13 and Anaconda. Key libraries that were used in this study are listed below: scikit-learn sc...
The PBMF ( Publised in Cancer cell ) is an automated neural network framework based on contrastive learning. This general-purpose framework explore...
# tigeR tigeR is an R package designed for exploring biomarkers and constructing predictive models for immunotherapy response via built-in or cus...
In order to identify miRNA target genes of immune-related signatures and pathways in cancer samples, we have developed the user-friendly web platfo...
NcRNA-encoded small peptides (ncPEPs) have recently emerged as promising targets and biomarkers for cancer immunotherapy. Therefore, identifying ca...
Recent Preprints
Mount Sinai Study Finds Antibody-Producing Immune Cells ...
Together, the findings show that PD-1 therapy triggers a coordinated immune responsein whichantibodies and T cells work together to fight cancer.
Towards biomarker-driven cancer immunotherapy
Identifying biomarkers for therapeutic response and resistance has been the holy grail of ICB therapy. Ovarian cancer ranks the third for incidence and the second for mortality among gynecological ...
Cancer Biomarkers: Reflection on Recent Progress, Emerging ...
This perspective provides a short overview of cancer biomarkers, balancing the technical details with the broad implications for biomarker discovery and innovation; early detection and screening; p...
Biomarker prediction of immunotherapy response in breast cancer: from single markers to multi-omics integration
Immunotherapy has redefined treatment paradigms across several malignancies, yet its application in breast cancer remains limited to select subtypes, particularly triple-negative breast cancer. As ...
Longitudinal liquid biopsy identifies an early predictive biomarker of immune checkpoint blockade response in head and neck squamous cell carcinoma
immunotherapy across cancer types.
Latest Developments
Recent developments in cancer immunotherapy and biomarkers research as of February 2026 include the advancement of smarter cell therapies, personalized vaccines, and combination strategies to reshape tumor microenvironments (AACR). Notably, a study from Mount Sinai identified IgG1 plasma cells as potential biomarkers to predict patient response to PD-1 checkpoint inhibitors (Mount Sinai). Additionally, innovative approaches such as personalized neoantigen-reactive T cell therapies and neoantigen vaccines are showing promising results in clinical trials (Nature, Nature).
Sources
Frequently Asked Questions
What is the response rate of anti-PD-1 antibody in cancer patients?
Anti-PD-1 antibody produced objective responses in approximately one in four to one in five patients with non-small-cell lung cancer, melanoma, or renal-cell cancer. Preliminary data suggest a relationship between PD-L1 expression on tumor cells and response rates. This profile supports its use across these indications.
How does pembrolizumab compare to chemotherapy in PD-L1-positive non-small-cell lung cancer?
In patients with advanced NSCLC and PD-L1 expression on at least 50% of tumor cells, pembrolizumab significantly prolonged progression-free survival and overall survival compared to platinum-based chemotherapy. It also resulted in fewer adverse events. This was demonstrated in the KEYNOTE-024 trial.
What role does mismatch-repair deficiency play in immunotherapy response?
Mismatch-repair status predicts clinical benefit from immune checkpoint blockade with pembrolizumab. Tumors with mismatch-repair deficiency showed responses to PD-1 blockade. This finding comes from a phase 2 trial across multiple cancer types.
What are common biomarkers for immunotherapy response?
Biomarkers include PD-L1 expression on tumor cells, tumor mutational burden, and mismatch-repair deficiency. PD-L1 levels correlate with anti-PD-1 response in lung cancer and melanoma. These markers help select patients likely to benefit from checkpoint inhibitors.
What adverse effects occur with immune checkpoint inhibitors?
Immune checkpoint inhibitors cause immune-related adverse events, including renal effects like acute kidney injury. Anti-CTLA-4 and anti-PD-1 therapies engage the immune system against tumors but can lead to off-target inflammation. Management strategies are outlined in reviews of cancer patient cohorts.
Open Research Questions
- ? How can multi-omics integration improve biomarker prediction for immunotherapy response in breast cancer subtypes?
- ? What early liquid biopsy markers, such as ctDNA, best predict immune checkpoint blockade response in head and neck squamous cell carcinoma?
- ? Which coordinated immune responses between antibodies and T cells are triggered by PD-1 therapy in solid tumors?
- ? How do tumor microenvironment factors contribute to resistance in ovarian cancer immunotherapy?
- ? What novel biomarkers predict responses to combination therapies involving checkpoint inhibitors?
Recent Trends
Field spans 134,991 papers with focus on biomarkers for response and resistance.
Preprints highlight multi-omics integration in breast cancer and ctDNA for real-time monitoring in trials.
Funding surges include $23.7 million to City of Hope for biomarker mapping and $3 million to University of Houston for an immunotherapy biomarker core.
OncoHost secured €2.5 million for a predictive biomarker in precision oncology.
Research Cancer Immunotherapy and Biomarkers with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching Cancer Immunotherapy and Biomarkers with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers